Literature DB >> 9367745

Mapping of linear histone regions exposed at the surface of the nucleosome in solution.

C Stemmer1, J P Briand, S Muller.   

Abstract

Antibodies directed against defined regions of histone molecules represent one of the most specific probes for studying the topography and conformational changes of nucleosomes and chromatin. We have developed an assay involving a series of monoclonal and polyclonal antibody probes specifically reacting with a complete set of 40 overlapping synthetic peptides (6 to 28 residues long) covering the whole sequence of the four core histones H2A, H2B, H3 and H4. In this assay, mono-, di- and trinucleosomes, as well as a long chain of chromatin containing 20 to 35 nucleosomes, were used in solution as competitors of the antibody reaction. At least 11 surface-oriented linear regions were characterized on the mononucleosome; namely, the N-terminal domains of H2A (residues 1 to 20), H2B (residues 1 to 25) and H3 (residues 1 to 30), the C-terminal domains of H2A (residues 116 to 129) and H4 (residues 85 to 102), and six domains located in internal segments in the primary structures of core histones (33 to 49 H2A, 65 to 85 H2A, 60 to 78 H2B, 50 to 70 H3, 111 to 130 H3 and 42 to 59 H4). Only a few changes in the nucleosome topography were observed when free oligo- and polynucleosome structure were comparatively studied.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367745     DOI: 10.1006/jmbi.1997.1270

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  12 in total

1.  A conserved organization of transcription during embryonic stem cell differentiation and in cells with high C value.

Authors:  Inês Faro-Trindade; Peter R Cook
Journal:  Mol Biol Cell       Date:  2006-04-19       Impact factor: 4.138

Review 2.  The anti-DNA antibody: origin and impact, dogmas and controversies.

Authors:  Ole P Rekvig
Journal:  Nat Rev Rheumatol       Date:  2015-06-02       Impact factor: 20.543

3.  Major peptide autoepitopes for nucleosome-specific T cells of human lupus.

Authors:  L Lu; A Kaliyaperumal; D T Boumpas; S K Datta
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

4.  Bovine herpesvirus 1 tegument protein VP22 interacts with histones, and the carboxyl terminus of VP22 is required for nuclear localization.

Authors:  X Ren; J S Harms; G A Splitter
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Kinetics of core histones in living human cells: little exchange of H3 and H4 and some rapid exchange of H2B.

Authors:  H Kimura; P R Cook
Journal:  J Cell Biol       Date:  2001-06-25       Impact factor: 10.539

6.  Identification of autoreactive B cells with labeled nucleosomes.

Authors:  Vincent Gies; Alain Wagner; Cécile Seifert; Aurélien Guffroy; Jean-D Fauny; Anne-M Knapp; Jean-L Pasquali; Thierry Martin; Hélène Dumortier; Anne-S Korganow; Pauline Soulas-Sprauel
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

7.  Phenotyping of autoreactive B cells with labeled nucleosomes in 56R transgenic mice.

Authors:  Vincent Gies; Delphine Bouis; Mickaël Martin; Jean-L Pasquali; Thierry Martin; Anne-S Korganow; Pauline Soulas-Sprauel
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

8.  Extracellular Chromatin Triggers Release of Soluble CEACAM8 Upon Activation of Neutrophils.

Authors:  Matthieu Ribon; Julie Mussard; Luca Semerano; Bernhard B Singer; Patrice Decker
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 9.  Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus.

Authors:  Sean Robinson; Ranjeny Thomas
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

10.  Circulating TFH subset distribution is strongly affected in lupus patients with an active disease.

Authors:  Carole Le Coz; Aurélie Joublin; Jean-Louis Pasquali; Anne-Sophie Korganow; Hélène Dumortier; Fanny Monneaux
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.